Welcome to our dedicated page for Solesence SEC filings (Ticker: SLSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solésence, Inc. (Nasdaq: SLSN) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its operations as a scientifically driven health care solutions company in beauty and life science categories. These SEC filings cover its activities in mineral-based skin care, sun care and color cosmetics, as well as its broader corporate and financial structure.
On this page, investors can review Solésence’s periodic reports, such as its Form 10-K referenced in company press releases, which describe risk factors, dependence on key customers, intellectual property around engineered materials and technologies, and other aspects of its household and personal products business. Quarterly results are often accompanied by Form 8-K filings under Item 2.02, in which Solésence furnishes earnings press releases detailing revenue composition, gross profit, operating expenses and non-GAAP metrics.
Additional Form 8-K filings document material events, including leadership transitions, employment agreements with senior executives, settlements related to commercial disputes, and outcomes of the annual meeting of stockholders. Proxy materials such as the DEF 14A provide information on the company’s classified board, equity compensation plan approvals and auditor ratification, as well as voting results.
Through Stock Titan, users can access these Solésence filings as they are made available on EDGAR and use AI-powered summaries to interpret lengthy documents. The platform can highlight key points from 10-K and 10-Q reports, explain the implications of 8-K items, and surface information related to executive arrangements and shareholder approvals. Filings related to equity compensation, board structure and customer or financing arrangements are particularly relevant for understanding Solésence’s governance and its position within the consumer defensive sector.
Solésence, Inc. reports strong 2025 growth as it advances its rebranding from Nanophase Technologies into a skin-health focused consumer products company. Total revenue rose to $62,064, driven mainly by prestige beauty consumer products built on its Active Stress Defense™ technology and mineral-based UV protection APIs.
The company increasingly prioritizes finished “white label” and custom skin-care products over legacy advanced materials, operates two FDA-registered, ISO-certified facilities near Chicago, and invests heavily in R&D and capacity to meet what management describes as unprecedented demand from brand partners.
Solésence, Inc. reported record full-year 2025 revenue of $62.1 million, up 19% from $52.3 million, as it expanded its SPF-infused beauty product portfolio. Despite higher sales, full-year gross margin fell to 26% from 31% and net income declined to $1.8 million from $4.2 million, reflecting higher operating costs.
In the fourth quarter, revenue was $12.5 million, roughly flat year over year, but gross margin improved to 27% from 22%, turning a net loss of $0.6 million in 2024’s quarter into net income of $0.2 million. The company highlighted its “Transform & Transcend” initiative, aimed at operational excellence, technology-driven market expansion, service model innovation, and global growth with brand partners, alongside adding 20 new brand partners and securing 16 new patents.
Solésence, Inc. disclosed details of a separation agreement with former CEO Jess Jankowski following his previously reported resignation as an officer. Under the agreement, effective December 2, 2025, Jankowski will receive severance pay totaling $366,912, accelerated vesting of all his outstanding stock options, and continued company-paid health insurance premiums under COBRA for the duration of the severance period. In return, he is providing a broad release of claims against the company and reaffirming obligations such as restrictive covenants and assistance in certain potential disputes. The separation agreement is filed as an exhibit to this report, with some portions redacted as confidential.
Solésence, Inc. filed a Form 8‑K to furnish information under Item 2.02 (Results of Operations and Financial Condition). The company reported that it issued a press release, which is attached as Exhibit 99.1 and incorporated by reference.
The filing also includes a “Solésence Third Quarter 2025 Conference Call Script” as Exhibit 99.2. These materials provide the company’s communications around its quarterly results, with the exhibits serving as the official source documents.
Solésence, Inc. reported Q3 2025 results with total revenue of $14,597, down from $16,866 a year ago, and a net loss of $1,120 versus prior-year income of $3,045. Gross profit was $3,370 compared with $6,102 as cost of revenue rose to $11,227. Selling, general and administrative expense increased to $3,069, reflecting higher legal, credit loss allowance, employee and NASDAQ uplisting costs.
For the nine months, revenue reached $49,581, up from $39,780, and net income was $1,627 versus $4,793. Cash was $429 at quarter end, with operating cash outflow of $10,386 and financing inflows of $11,099, including related-party credit facilities. Accounts receivable, net, increased to $9,709 and the allowance for credit losses to $1,729. Three customers represented 60% of Q3 revenue.
Other items included recognition of $1,234 from the Employee Retention Credit and $194 of related interest. A confidential settlement provides for a $675 payment to Solésence by January 15, 2026. The company also notes BASF supply agreement contingencies that could impact equipment and revenue if triggered.
Solésence, Inc. entered a settlement agreement with Solarium Brands, LLC and A-Frame Brands, LLC to resolve disputes related to previously sold consumer care products. Under the agreement, Solarium will make a one-time settlement payment of $675,000 to Solésence on or before January 15, 2026.
The agreement finalizes a commercial dispute and provides for a defined payment to Solésence. The full agreement was filed with certain confidential portions redacted.
Solesence, Inc. reported an initial Form 3 disclosing that Laura C. Riffner became Chief Financial Officer and received an option to purchase 60,000 shares of common stock on 09/03/2025. The option vests in three equal annual installments beginning 09/03/2026 and expires on 09/03/2032, with a strike price set at the NASDAQ closing price on the grant date. The filing was signed on 10/06/2025 and notes delays due to CIK availability and EDGAR Next technical issues.
Solésence, Inc. announced leadership changes alongside new employment agreements for its top executives. Kevin Cureton, age 64, who has been Chief Operating Officer since 2019, has been appointed Chief Executive Officer and President, effective September 3, 2025. Former CEO and CFO Jess Jankowski will transition to serve as Board Advisor until his planned retirement on November 21, 2025.
Laura Riffner, age 53, was appointed Chief Financial Officer as of September 3, 2025. She brings prior CFO and finance leadership experience from Nagase America and Paxton/Patterson, and is a licensed Certified Public Accountant. Under their agreements, Mr. Cureton’s annual base salary will be not less than $367,000, Mr. Jankowski’s transition salary will be not less than $366,912 through retirement, and Ms. Riffner’s annual base salary will be not less than $270,000, with Cureton and Riffner eligible for bonuses and stock option grants under the company’s equity plan.
Solésence, Inc. reported the results of its Annual Meeting of Shareholders held on August 28, 2025. Shareholders representing 61,205,907 shares, or about 86.83% of the 70,481,945 shares outstanding as of July 21, 2025, were present or represented by proxy, providing a quorum.
Two director nominees were elected: R. Janet Whitmore received 55,548,531 votes for, with 1,019,946 votes withheld and 4,637,430 broker non-votes; Laura M. Beres received 55,853,069 votes for, with 715,408 votes withheld and 4,637,430 broker non-votes.
Shareholders approved the Company’s 2025 Equity Compensation Plan with 56,301,567 votes for, 207,542 votes against, 59,368 abstentions, and 4,637,430 broker non-votes. They also ratified the appointment of RSM US LLP as independent registered public accounting firm for fiscal year 2025, with 61,074,473 votes for, 122,447 votes against, and 8,987 abstentions.
Solésence, Inc. (SLSN) reported stronger revenue and higher expenses for the quarter and first half of 2025 compared with 2024. Revenue for the three months ended June 30, 2025 was $20,359 thousand versus $13,046 thousand a year earlier, and revenue for the six months was $34,984 thousand versus $22,914 thousand. Total expense for Q2 2025 was $17,692 thousand versus $12,190 thousand in Q2 2024 (six months: $32,237 thousand versus $21,167 thousand). Operating activities used $7,875 thousand in cash in the period while financing activities provided $11,849 thousand. The company amended related-party credit facilities in May 2025 to increase accounts receivable and inventory revolvers and extended maturities to April 30, 2027. Management recognized $1,234 thousand of an Employee Retention Credit and recorded a $572 thousand reserve for the excess payment as a contingent liability included in accrued expenses.